Foundation Medicine at International Society of Liquid Biopsy (ISLB) 2024 6th Annual Congress

Please join Dr. Mia Levy and Dr. Valsamo Anagnostou Sunday, November 24 to explore the transformative role of circulating tumor DNA (ctDNA) in modern cancer care: ctDNA Revolution: Shaping the Future of Cancer Care with Next Generation Biomarkers and Real-Time Treatment Monitoring.

Foundation Medicine is thrilled to support the International Society of Liquid Biopsy (ISLB) 2024 6th Annual Congress in Denver, CO, November 23-25. Learn how ctDNA tumor fraction*, reported with FoundationOne®Liquid CDx results, can deliver greater confidence in results to help guide next steps in patient care.

With FoundationOne®Liquid CDx, you can unlock the power of evidence-based insights. FoundationOne Liquid CDx with ctDNA tumor fraction* can help you determine when liquid biopsy is likely to be concordant to tissue and when, or if, reflexing to tissue might uncover additional findings by reporting high/low ctDNA levels in patient reports.

Please stop by Booth #302 to meet our team and discover why Foundation Medicine’s liquid biopsy is different. Not all comprehensive genomic profiling testing is created equal.  

Click here to schedule a meeting during the congress.